Atara Biotherapeutics Inc (ATRA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Atara Biotherapeutics Inc stock (ATRA) is currently trading at $4.99. Atara Biotherapeutics Inc PE ratio is 1.91. Atara Biotherapeutics Inc PS ratio (Price-to-Sales) is 0.33. Analyst consensus price target for ATRA is $5.00. WallStSmart rates ATRA as Sell.
- ATRA PE ratio analysis and historical PE chart
- ATRA PS ratio (Price-to-Sales) history and trend
- ATRA intrinsic value — DCF, Graham Number, EPV models
- ATRA stock price prediction 2025 2026 2027 2028 2029 2030
- ATRA fair value vs current price
- ATRA insider transactions and insider buying
- Is ATRA undervalued or overvalued?
- Atara Biotherapeutics Inc financial analysis — revenue, earnings, cash flow
- ATRA Piotroski F-Score and Altman Z-Score
- ATRA analyst price target and Smart Rating
Atara Biotherapeutics Inc
📊 No data available
Try selecting a different time range
ATRA Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Atara Biotherapeutics Inc (ATRA)
ATRA trades at a significant discount to its Graham intrinsic value of $17.48, offering a 74% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Atara Biotherapeutics Inc (ATRA) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, profit margin. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Atara Biotherapeutics Inc (ATRA) Key Strengths (3)
Paying less than $1 for every $1 of annual revenue
Keeps $27 of every $100 in revenue as net profit
Trading at 1.97x book value, attractively priced
Supporting Valuation Data
Atara Biotherapeutics Inc (ATRA) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -95.10%, a shrinking business
Micro-cap company with very limited liquidity and high volatility
Moderate institutional interest at 41.93%
Supporting Valuation Data
Atara Biotherapeutics Inc (ATRA) Detailed Analysis Report
Overall Assessment
This company scores 39/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 9.3/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Profit Margin, Price/Book. Valuation metrics including Price/Sales (0.33), Price/Book (1.97) suggest the stock is attractively priced. Profitability is solid with Profit Margin at 27.10%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Growth concerns include Revenue Growth at -95.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -2015.00%, Operating Margin at -339.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -2015.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -95.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ATRA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ATRA's Price-to-Sales ratio of 0.33x sits near its historical average of 0.29x (86th percentile), suggesting the market is pricing in steady-state growth. The current valuation is -1% below its historical high of 0.33x set in Mar 2026, and 45% above its historical low of 0.23x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~0.3x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Atara Biotherapeutics Inc (ATRA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Atara Biotherapeutics Inc faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 121M with 95% decline year-over-year. Profit margins are strong at 27.1%, reflecting pricing power and operational efficiency.
Key Findings
Revenue contracted 95% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Atara Biotherapeutics Inc.
Bottom Line
Atara Biotherapeutics Inc faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Atara Biotherapeutics Inc(ATRA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Atara Biotherapeutics, Inc., a commercially available T-cell immunotherapy company, develops treatments for cancer patients, autoimmune and viral diseases in the United States. The company is headquartered in South San Francisco, California.